This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mink, S. A. Articles by Armitage, J. O. Search for Related Content PubMed PubMed Citation Articles by Mink, S. A. Articles by Armitage, J. O.

High-Dose Therapy in Lymphomas: A Review of the Current Status of Allogeneic and Autologous Stem Cell Transplantation in Hodgkin's Disease and Non-Hodgkin's Lymphoma

University of Nebraska Medical Center, Section of Oncology/Hematology, Omaha, Nebraska, USA

Correspondence: Scott Mink, M.D., University of Nebraska Medical Center, Section of Oncology/Hematology, Box 987680, Omaha, Nebraska 68164-7680, USA. Telephone: 402-559-6210; Fax: 402-559-6520; e-mail: smink{at}unmc.edu.

Autologous stem cell transplantation has proven to be beneficial in selected patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). In patients with HD, transplantation appears to increase event-free survival in patients who fail to enter complete remission with initial therapy. When a patient relapses after a complete remission, transplantation is probably the best option and particularly so if the remission lasted less than 1 year. Transplantation as part of primary therapy for very high-risk patients may be beneficial, but is not standard therapy at this time. For patients with diffuse large-cell NHL, transplantation can be considered standard therapy for relapsed patients if they have chemotherapy-sensitive disease. The use of transplantation for high-risk patients in complete remission is promising, but definite recommendations cannot be made at this time. For follicular lymphomas, selected patients seem to benefit and studies are ongoing. Finally, the use of allogeneic stem cell transplantation can be useful in a select group of younger patients.

Key Words. Non-Hodgkin's lymphoma • Hodgkin's disease • Autologous transplantation • Allogeneic transplantation • Review • High-dose therapy • Hematopoietic stem cell transplantation

This article has been cited by other articles:

				A. Gondos, F. Bray, T. Hakulinen, H. Brenner, and the EUNICE Survival Working Group Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis Ann. Onc., March 1, 2009; 20(3): 564 - 573. [Abstract] [Full Text] [PDF]

				K. A. Goodman, E. Riedel, V. Serrano, S. Gulati, C. H. Moskowitz, and J. Yahalom Long-Term Effects of High-Dose Chemotherapy and Radiation for Relapsed and Refractory Hodgkin's Lymphoma J. Clin. Oncol., November 10, 2008; 26(32): 5240 - 5247. [Abstract] [Full Text] [PDF]

				T Mitterlechner, M Fiegl, H Muhlbock, W Oberaigner, S Dirnhofer, and A Tzankov Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000 J. Clin. Pathol., January 1, 2006; 59(1): 48 - 55. [Abstract] [Full Text] [PDF]